Immunovia AB

IMMNOV

SE0006091997

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 11:29:50 2024-05-28 EDT			5-day change	1st Jan Change
1.438 ^SEK	+1.99%		+18.26%	-18.85%

05-21	Immunovia Seeks SEK70 Million from Proposed Rights Offering	MT
04-29	Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024

Presentation Operator MessageOperator (Operator)Welcome to the Immunovia Audiocast Teleconfere...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Immunovia AB

Immunovia Seeks SEK70 Million from Proposed Rights Offering	05-21	MT
Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024	04-29
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina	04-29	CI
Immunovia Appoints Lisa Ford as Clinical Laboratory Director	04-29	CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	04-22	CI
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	04-09	MT
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	04-09	CI
Transcript : Immunovia AB, 2023 Earnings Call, Feb 21, 2024	02-21
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members	11-21	CI
Transcript : Immunovia AB, Q3 2023 Earnings Call, Nov 09, 2023	11-09
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test	11-07	MT
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	11-07	CI
Immunovia AB Announces Board Appointments	23-10-03	CI
Transcript : Immunovia AB, H1 2023 Earnings Call, Aug 30, 2023	23-08-30
Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Transcript : Immunovia AB - Special Call	23-07-12
Sweden's Immunovia Redirects Resources Towards Development of New Pancreatic Cancer Detection Test	23-07-12	MT
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection	23-07-11	CI
Immunovia AB Announces Board Changes	23-05-26	CI
Transcript : Immunovia AB, Q1 2023 Earnings Call, May 23, 2023	23-05-23
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâs test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-19 - Annual General Meeting

More about the company

	1st Jan change	Capi.
IMMUNOVIA AB	-18.85%	6.02M
SARTORIUS AG	-25.18%	17.05B
QUIDELORTHO CORPORATION	-40.23%	2.84B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+15.23%	1.85B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-5.65%	1.56B
BIOTAGE AB	+33.13%	1.36B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-18.62%	924M
CONTEC MEDICAL SYSTEMS CO.,LTD	-25.88%	856M
VAREX IMAGING CORPORATION	-26.78%	604M
CELLAVISION AB	+24.29%	573M